The Latest Breaking News from Moderna

Unusual Options Activity in Microsoft Stock Is Already Paying Off (and 3 Other Stocks to Watch)

Microsoft's 14,875-contract bull call spread ($525/$600, Oct. 30) gained 3% in one day. For non-tech alternatives, Robinhood's $123/$128 call spread, Moderna's $195/$205 combo (already profitable), and ExxonMobil's $167.50/$172.50 spread offer varying risk/reward, though XOM's breakeven exceeds its analyst target price.

Barchart · Sep 25

Opinion: The First Personalized mRNA Cancer Vaccine Just Passed a Major Test: Now Comes the Hard Part

A late-stage trial found that a custom-built mRNA therapy added to immunotherapy reduced melanoma recurrence. An oncologist argues the result is a genuine milestone, but patients deserve clear answers on the size of the benefit, survival, cost, and access before the hype takes over.

Medical Daily · Sep 23

Moderna's Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson's drug

CI is pairing top AI and biotech minds on its board (plus an advisory role for OpenAI's Fidji Simo) as it tests models on a Novo Nordisk drug.

Fortune · Sep 21

Dolly Parton once gave $1 million to help develop the Moderna COVID vaccine at Vanderbilt: ‘I’m kind of addicted to the feeling of giving’

Dolly Parton had a $450 million fortune at her passing, but spent much of her life giving it away—including $1 million toward COVID-19 vaccine research.

Fortune · Aug 26

Wolfe Research Just Upgraded Moderna Stock. Here's Why.

Moderna stock rallies as Wolfe Research upgrades it to "Peer Perform." But is there any further upside left in MRNA shares? Let’s find out!

Barchart · Aug 25

US stocks today: US stocks close higher on tech rebound as Nvidia earnings gain focus

US stocks closed higher as technology and semiconductor shares recovered ahead of Nvidia's earnings. Lower oil prices and Treasury yields offered relief, while investors assessed AI spending and stretched valuations. Weak consumer confidence added to economic concerns, with upcoming PCE inflation data and Fed commentary keeping rate expectations in focus.

The Economic Times · Aug 25

Moderna Added 45 Billion Dollars in a Day on a Melanoma Vaccine Result with No Effect Size Disclosed

Moderna and Merck's melanoma vaccine met its Phase 3 goals, but no effect size was released, and some analysts called the market reaction excessive.

Medical Daily · Aug 25

BioNTech Moved Higher as the Broader Biotech Sector Hit a Post-Pandemic Peak, but BNTX Stock Needs Stronger Fundamentals to Keep Climbing

BioNTech shares moved higher as the broader biotech sector reached a post-pandemic peak, lifted by positive late-stage cancer vaccine data from peers rather than new clinical results of its own.

Barchart · Aug 24

2 Biotech Stocks Shaping Up for Major Breakouts

Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.

MarketBeat · Aug 22

Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.

Moderna's cancer treatment could treat more than just Melanoma, though the stock's momentum is already stalling. Should you still buy the dip?

Barchart · Aug 21